Jeffrey Rathmell, PhD

Official Affiliation: Pathology, Microbiology & Immunology

Profile

No cell can survive or act without the appropriate nutrients and metabolic program.  There has been a growing appreciation that metabolism is intimately linked to nearly all aspects of cell function and fate.  The field of immunometabolism aims to understand how metabolic pathways are regulated in immune cells, how specific metabolic programs alter immune function, and how immunity in turn may influence metabolism.  The Rathmell lab focuses on how metabolic pathways influence the function and fate of lymphocytes in inflammatory diseases, anti-tumor immunity, and in leukemia.  Our work is highly interdisciplinary and involves the fields of immunology, cancer biology, and cell metabolism. Ultimately the goals of these projects are to exploit the specific metabolic programs of each cell type or activation state to selectively impact effector lymphocytes in inflammatory diseases and cancer. 

 

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Oligodeoxynucleotides ODN 2006 and M362 Exert Potent Adjuvant Effect through TLR-9/-6 Synergy to Exaggerate Mammaglobin-A Peptide Specific Cytotoxic CD8+T Lymphocyte Responses against Breast Cancer Cells. Babaer D, Amara S, McAdory BS, Johnson O, Myles EL, Zent R, Rathmell JC, Tiriveedhi V (2019) Cancers (Basel) 11(5)
    › Primary publication · 31091800 (PubMed) · PMC6562487 (PubMed Central)
  2. Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8 T cells. Gemta LF, Siska PJ, Nelson ME, Gao X, Liu X, Locasale JW, Yagita H, Slingluff CL, Hoehn KL, Rathmell JC, Bullock TNJ (2019) Sci Immunol 4(31)
    › Primary publication · 30683669 (PubMed) · PMC6824424 (PubMed Central)
  3. Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism. Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, Maseda D, Liberti MV, Paz K, Kishton RJ, Johnson ME, de Cubas AA, Wu P, Li G, Zhang Y, Newcomb DC, Wells AD, Restifo NP, Rathmell WK, Locasale JW, Davila ML, Blazar BR, Rathmell JC (2018) Cell 175(7): 1780-1795.e19
    › Primary publication · 30392958 (PubMed) · PMC6361668 (PubMed Central)
  4. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. Siska PJ, Beckermann KE, Mason FM, Andrejeva G, Greenplate AR, Sendor AB, Chiang YJ, Corona AL, Gemta LF, Vincent BG, Wang RC, Kim B, Hong J, Chen CL, Bullock TN, Irish JM, Rathmell WK, Rathmell JC (2017) JCI Insight 2(12)
    › Primary publication · 28614802 (PubMed) · PMC5470888 (PubMed Central)

Featured Affiliation

View all affiliations

Contact Information

No address provided
Email

Keywords & MeSH Terms

MeSH terms are retrieved from PubMed records. Learn more.

Key: MeSH Term Keyword

Animals Antineoplastic Agents, Immunological CD8-Positive T-Lymphocytes Cell Differentiation Cell Line, Tumor Glucose Glucose Transporter Type 1 Glut1 Glutaminase Glycolysis Hepatitis A Virus Cellular Receptor 2 Humans Immunoglobulin G Immunotherapy, Adoptive inflammation Lymphocyte Activation Lymphocytes, Tumor-Infiltrating Male Melanoma metabolism Mice Mice, Inbred C57BL Mice, Transgenic Phosphopyruvate Hydratase Programmed Cell Death 1 Receptor T cell Th1 Cells Th17 Cells tumor immunology